Ionis Pharmaceuticals 将来の成長

Future 基準チェック /26

Ionis Pharmaceuticals利益と収益がそれぞれ年間32.9%と21.9%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-145.2% 33.5%なると予測されています。

主要情報

32.9%

収益成長率

33.5%

EPS成長率

Biotechs 収益成長	0%
収益成長率	21.9%
将来の株主資本利益率	-145.2%
アナリストカバレッジ	Good
最終更新日	18 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BMV:IONS * - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	957	-429	-422	-274	17
12/31/2025	730	-553	-530	-380	24
12/31/2024	623	-516	-414	-365	24
9/30/2024	803	-359	-374	-352	N/A
6/30/2024	813	-366	-375	-346	N/A
3/31/2024	777	-385	-345	-323	N/A
12/31/2023	788	-366	-336	-308	N/A
9/30/2023	615	-409	-574	-541	N/A
6/30/2023	631	-309	-493	-456	N/A
3/31/2023	576	-329	-405	-377	N/A
12/31/2022	587	-270	-294	-274	N/A
9/30/2022	875	7	110	130	N/A
6/30/2022	849	-28	82	98	N/A
3/31/2022	841	-4	35	54	N/A
12/31/2021	810	-29	13	31	N/A
9/30/2021	661	-608	-96	-75	N/A
6/30/2021	688	-550	-59	-30	N/A
3/31/2021	708	-495	-45	-11	N/A
12/31/2020	729	-444	-5	36	N/A
9/30/2020	933	94	173	216	N/A
6/30/2020	940	145	165	213	N/A
3/31/2020	959	169	188	230	N/A
12/31/2019	1,123	281	309	346	N/A
9/30/2019	821	433	154	183	N/A
6/30/2019	799	402	154	170	N/A
3/31/2019	752	366	679	697	N/A
12/31/2018	600	277	585	603	N/A
9/30/2018	575	-41	485	508	N/A
6/30/2018	548	-38	N/A	563	N/A
3/31/2018	543	9	N/A	65	N/A
12/31/2017	514	19	N/A	174	N/A
9/30/2017	507	42	N/A	127	N/A
6/30/2017	499	52	N/A	122	N/A
3/31/2017	426	-15	N/A	86	N/A
12/31/2016	373	-60	N/A	-112	N/A
9/30/2016	238	-184	N/A	-123	N/A
6/30/2016	176	-227	N/A	-111	N/A
3/31/2016	258	-134	N/A	-12	N/A
12/31/2015	284	-88	N/A	21	N/A
9/30/2015	317	14	N/A	129	N/A
6/30/2015	312	23	N/A	95	N/A
3/31/2015	249	-24	N/A	-4	N/A
12/31/2014	214	-39	N/A	6	N/A
9/30/2014	172	-94	N/A	-79	N/A
6/30/2014	151	-92	N/A	-15	N/A
3/31/2014	132	-90	N/A	42	N/A
12/31/2013	147	-61	N/A	63	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IONS *今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IONS *今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: IONS *今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IONS *の収益 ( 21.9% ) MX市場 ( 7.3% ) よりも速いペースで成長すると予測されています。

高い収益成長: IONS *の収益 ( 21.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IONS * 3 年以内に赤字になると予測されています。

Ionis Pharmaceuticals 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Ionis Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Ionis Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Recent updates

Insufficient new directors

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Astrazeneca and Ionis' Wainzua (Eplontersen) Recommends Approval by the Committee for Medicinal Products for Human Use in the European Union

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Zilganersen Granted U.S. FDA Fast Track Designation for People Living with Alexander Disease

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Insufficient new directors

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.45 loss per share (vs US$0.60 loss in 2Q 2023)

Ionis Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2024

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Detailed Results from the HALOS Study of ION582 in People with Angelman Syndrome

Ionis Pharmaceuticals, Inc. Announces olezarsen FCS New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed

Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome

Ionis Presents Positive Two-Year Results from the Phase 2 Open-Label Extension Study of Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Ionis Pharmaceuticals, Inc. Announces Positive Olezarsen Topline Results from Phase 3 Study in People with Facilitate Chylomicronemia Syndrome

Insufficient new directors

Ionis Completes Enrollment in Phase 3 Cardio-TTRansform Study in Patients with TTR-Mediated Amyloid Cardiomyopathy

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Ionis Pharmaceuticals, Inc. Announces Positive Topline, 85-Week Data from the Phase 3 Neuro-Ttransform Study in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Ionis Pharmaceuticals, Inc. Announces New Data Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Medical Needs After Gene Therapy

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Donidalorsen Late-Stage Clinical Progress in HAE

Ionis Pharmaceuticals, Inc. Announces GSK Has Advanced Bepirovirsen into Phase 3 Development

Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces European Medicines Agency Accepts Marketing Authorization Application of Tofersen to Treat Rare, Genetic Form of ALS

Ionis Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

Ionis Pharmaceuticals, Inc. Announces Positive Data from GSK's Phase 2b Clinical Study of Bepirovirsen

Ionis Pharmaceuticals, Inc. Presents Positive Phase 2 Data in Patients with IgA Nephropathy At American Society of Nephrology's Kidney Week 2022

Ionis Pharmaceuticals, Inc. Announces Positive Results from Fesomersen Development Program

Oxford Properties Group, Inc. acquired 18.4-Acre Life Science Campus and Corporate Headquarters of Ionis Pharmaceutical in San Diego from Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS).

Ionis Pharmaceuticals, Inc. Provides Update on Development Program Evaluating PCSK9 Antisense Medicine for the Treatment of Hypercholesterolemia

Ionis Pharmaceuticals, Inc. Presents Positive Results from Phase 3 Neuro-Ttransform Study At International Symposium on Amyloidosis

Second quarter 2022 earnings released: US$0.74 loss per share (vs US$0.57 loss in 2Q 2021)

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 2B Clinical Study of Fesomersen

Ionis Pharmaceuticals, Inc. Announces FDA Accepts New Drug Application and Grants Priority Review of Tofersen for A Rare, Genetic Form of ALS

Ionis Announces Enrollment Completion of Phase 3 Lp(a) HORIZON Cardiovascular Outcomes Study of Pelacarsen

Frederick Muto Retires from Ionis Pharmaceuticals, Inc., Effective July 15, 2022

Insufficient new directors

Ionis Partner Licenses Rare Kidney Disease Treatment and Will Advance into Phase 3 Clinical Study

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Presentation of Positive Phase 2B Data for Chronic Hepatitis B Treatment At the EASL International Liver Congress™

Ionis Announces Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the Phase 3 Neuro-Ttransform Study for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)

Ionis Pharmaceuticals, Inc. Announces Results from the Phase 3 Valor Study and Its Open-Label Extension of tofersen

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘